Teva Pharmaceuticals (TEVA 0.43%) has been engulfed with turmoil. Its blockbuster MS franchise is facing a new competitive thereat, and the company is staring down the barrel of its patent expiration. Then in October, we saw the surprise departure of still-new-on-the-job CEO Jeremy Levin.
Teva has not stood still. This past week has seen the company jump into the bidding for NuPathe (NASDAQ: PATH), topping Endo Health's (ENDP +0.00%) offer for the former's FDA-approved migraine patch. More importantly, it filled the vacancy in its CEO suite. Board member Erez Vigodman is set to take over, and has been hailed as an excellent choice, but he has a challenging road ahead.
In this video Motley Fool health-care analyst David Williamson discusses the competing NuPathe deals and what they mean for investors in both stocks, as well as the challenges Teva's new CEO will face and the important questions he must answer.
